anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Surgical cytoreduction for neuroendocrine tumor liver metastasis (NETLM) consistently shows positive long-term outcomes. Despite reservations in guidelines for surgery when the primary tumor is unidentified (UP-NET), this study compared the surgical and oncologic long-term outcomes between patients with these rare cases undergoing cytoreductive surgery and patients who had liver resection for known primaries.
METHODS: The study identified 32 unknown primary liver metastases (UP-NETLM) in 522 retrospectively evaluated patients who underwent resection of well-differentiated NETLM between January 2000 and December 2020. Tumor and patient characteristics were compared with those in 490 cases of liver metastasis from small intestinal (SI-NETLM) or pancreatic (pNETLM) primaries. Survival analysis was performed to highlight long-term outcome differences. Surgical outcomes were compared between liver resections alone and simultaneous primary resections to assess surgical risk distinctions.
RESULTS: The UP-NET patients had fewer NETLMs (p = 0.004), which on the average were larger than SI-NETLMs or pNETLMs (p = 0.002). Expression of Ki-67 was balanced among the groups. Major hepatectomy was performed more often in the UP-NETLM group (p = 0.017). The 10-year survival rate of 53% for UP-NETLM was comparable with that for SI-NETML (58%; p = 0.463) and pNETLMs (47%; p = 0.497). The median hepatic progression-free survival was 26 months for the UP-NETLM patients and 25 months for the SI-NETLM patients compared to 12 months for the pNETLM patients (p < 0.001). Perioperative mortality was lower than 2%, and severe postoperative morbidity occurred in 21%, similarly distributed among all the groups.
CONCLUSION: The surgical risk and long-term outcomes for the UP-NETLM patients were comparable with those for other NETLM cases, affirming the validity of equally aggressive surgical cytoreduction as a therapeutic option in carefully selected cases.
PURPOSE:To attain the fast retrieval of the past picture data on a patient of the second visit to a hospital by transferring previously the picture data to a fast file like a magnetic disk, etc., from a slow file like an optical disk, etc., based on the information on reception of the second visit. CONSTITUTION:A reception window 1 of a hospital is provided with a card reader 11 for ID card of the patients of the second visit and a second visit reception machine 12 which sends the read ID card to a medical picture control system 31. A consultation room 2 contains a picture display 21 and a semiconductor local memory 22 which is set as necessary. A computer room 3 contains the system 31 that controls an optical disk device 32 serving as a slow file for long-period preservation and a magnetic disk device 33 serving as a fast file for short-period preservation. At the time of the second visit is accepted, it is checked based on the ID card of the corresponding patient whether the past picture data are collected or not. If the past data are collected, it is checked again to decide whether said past picture data are stored in a slow file or a fast file. If said picture data are stored in then slow file, they are transferred to the fast file.
The SEBTC evaluation took place in the summers of 2011 through 2014. Ten grantees implemented the demonstration in a total of 16 sites; the number of participating sites and/or the evaluation components differed by year. In 2011, 5 grantees with five sites participated and the evaluation included implementation and cost analysis, EBT analysis, and an impact study. In 2012, 10 grantees implemented SEBTC in 14 sites and the evaluation included the same study components. In 2013, four grantees with six sites participated and the study components included EBT analysis and an impact study (no implementation or cost data collection). Finally, in 2014, three grantees participated in three sites and only implementation data were collected. Information on human subjects was collected for the evaluation's impact evaluation.
GENOSYL (nitric oxide) is administered by inhalation. Nitric oxide is a pulmonary vasodilator. Nitric oxide is generated from liquid dinitrogen tetroxide (N 2O 4) by the cassette in the GENOSYL Delivery System. Upon initiation of GENOSYL Delivery System, the liquid N 2O 4is heated and the equilibrium shifts to nitrogen dioxide (NO 2) gas. The NO 2is then converted into nitric oxide (NO) using the antioxidant cartridges, and nitric oxide is delivered to the patient by means of a ventilator or a nasal cannula. The amount of nitric oxide administered to the patient is set by controlling the temperature of the N 2O 4liquid module, which controls the pressure inside the liquid module, which in turn controls the mass of NO 2that is sent to the primary cartridges, and hence the mass of nitric oxide. The mass flow of nitric oxide, together with the air from the pump, control the nitric oxide concentration. A nitric oxide sensor monitors the nitric oxide in the patient line. GENOSYL Delivery System is designed to deliver a controlled level of nitric oxide blended with breathing air or oxygen-enriched breathing air. 

The GENOSYL Delivery System controls the flow of nitric oxide mixed with air delivered to the patient.

The structural formula of nitric oxide (NO) is shown below:
OBJECTIVES: Lung adenocarcinoma (LUAD) is a malignant tumor originating from the bronchial mucosa or glands of the lung, with the fastest increasing morbidity and mortality. Therefore, the prognosis of lung cancer remains poor. Glycerol-3-phosphate dehydrogenase 2 (GPD2) is a widely existing protein pattern sequence in biology and is closely related to tumor progression. The therapy values of GPD2 inhibitor in LUAD were unclear. Therefore, we aimed to analyze the therapy values of GPD2 inhibitor in LUAD.
MATERIALS AND METHODS: The Cancer Genome Atlas (TCGA)-LUAD database was used to analyze the expression levels of GPD2 in LUAD tissues. The relationship between GPD2 expression and LUAD patient survival was analyzed by Kaplan-Meier method. Moreover, KM04416 as a target inhibitor of GPD2 was used to further investigate the therapy value of GPD2 inhibitor in LUAD cells lines (A549 cell and H1299 cell). The TISIDB website was used to investigate the associations between GPD2 expression and immune cell infiltration in LUAD.
RESULTS: The results showed that GPD2 is overexpressed in LUAD tissues and significantly associated with poor survival. KM04416 can suppress the progression of LUAD cells by targeting GPD2. Low expression of GPD2 is related to high infiltration of immune cells.
CONCLUSIONS: In summary, our present study found that targeting inhibition of GPD2 by KM04416 can suppress LUAD progression via adjusting immune cell infiltration.
Patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily, and complete Resilient Living program in-person or remotely over 60 minutes. Patients also undergo CT scans throughout the trial.
A method is to prepare a raw material containing a moisturizing agent in a predetermined proportion, collect nanofibers with a predetermined area through the electrospinning equipment, cut a care product with a matched shape through a mold, and package the care product with the moisture retaining effect. The method makes a care product with the moisture retaining effect, which is a facial mask or a patch. The method uses electrospinning to produce nanofibers with the predetermined area, which become a carrier that is not easy to tear, can lock the raw material with the moisture retaining effect, can preserve the whitening ingredient for a long time before the skin absorbs them, and are not easy to deteriorate. The raw material includes an aqueous moisturizing agent. The moisturizing agent can be glycerin or propylene glycol. The raw material further includes one of gelatin, collagen, lignin, soybean protein, starch, polylactic acid, chitin, chitosan, polyvinyl alcohol, polycaprolactone, hydroquinone, kojic acid, vitamin C and its derivatives, tranexamic acid, fruit acid and water. The present invention also provides a body skin care product prepared by the above-described method, wherein the care product uses nanofibers with a predetermined area that are collected by electrospinning as a carrier. The carrier includes a moisturizing beauty care layer. The care product can be a facial mask or a patch. Thus, the present invention provides a method for preparing the body skin care product, which adopts a carrier that is not easy to tear to preserve the care product with the moisture retaining effect, and a body skin care product suitable for body skin beauty and care.
Disclosed is a pharmaceutical composition for oral administration in form of a tablet with extended release of clarithromycine in the gastrointestinal environment. The composition comprises clarithromycine and a pharmaceutically acceptable, hydrophilic, water soluble polymer that is hydroxypropylmethyl cellulose 2208 containing 19 % to 24 % of metoxyle, 7 % to 12 % of hydroxypropoxyle having 80 to 120 mPa.s viscosity, as 2 % water solution and having a such particle size that 100 % of the particles passes through the sieve with sieve mesh 595 micro m (30 mesh), more than 99 % of the particles passes through the sieve with sieve 400 micro m (40 mesh) and more than 90 % of the particles passes through the sieve with sieve 149 micro m (100 mesh). The tablet formulation comprises 500 mg of clarithromycine and 200 mg of polymer, 260 mg lactose monohydrate, 30 mg of talc USP and 10 mg of magnesium stearate. It is obtainable by wet process. The formulation releases clarithromycine in such a way, that after the single dose of 500 mg the area below the curve plasma concentration - time 0 - infinity is 15.0 + 6.5 ug.h/ml, the maximum concentration in the plasma is achieved after 5.0 + 1.7 hours after administration of the dose and maximum concentration in the plasma is 1.19 + 0.6 ug.h/ml. Further there is described use of the formulation for preparation of a medicine for bacterial infection treatment of mammals.
Circulating insulin levels are known to be increased in people with higher body mass index (BMI) due to effects of adiposity on insulin resistance, whilst gut hormones have a more complex relationship, with fasting peptideYY (PYY) reported to be inversely related to BMI. This study aimed to further explore fasting and post prandial pancreatic and gut hormone concentrations in plasma samples from obese and non-obese participants. Participants with healthy BMI (n=15), overweight BMI (n=29) and obesity (n=161) had samples taken fasting and 30 min post mixed liquid meal for analysis of glucagon-like peptide-1 (GLP-1), PYY, glucose-dependent insulinotropic polypeptide (GIP), insulin and glucagon. Data visualiation used linear discriminant analysis for dimensionality reduction, to visualise the data and assess scaling of each hormone. Fasting levels of insulin, GIP and PYY were shown to be key classifiers between the 3 groups on ANCOVA analysis, with an observation of increased GIP levels in overweight, but not obese participants. In non-obese subjects, fasting GIP, PYY and insulin correlated with BMI, whereas in subjects with obesity only the pancreatic hormones glucagon and insulin correlated with BMI. Concentrations of total GLP-1 in the fasting state correlated strongly with glucagon levels, highlighting potential assay cross-reactivities. The study, which included a relatively large number of subjects with severe obesity, supported previous evidence of BMI correlating negatively with fasting PYY and positively with fasting insulin. The observation of increased fasting GIP levels in overweight but not obese participants deserves further validation and mechanistic investigation.
The cerebellum plays an important role in cognitive and social functioning. Childhood damage in the cerebellum increases the risk of autism spectrum disorder. Cerebellar inflammation induces social avoidance in mice. Oxytocin regulates social relationship and expression pattern of the oxytocin receptor in the brain is related to social behaviors. However, the expression patterns of the oxytocin receptor in the cerebellum remain controversial. Here, we report that the expression patterns of the oxytocin receptor in the cerebellum are highly variable among knock-in transgenic lines. We used Oxtr-Cre knock-in mice combined with a fluorescent reporter line and found that oxytocin receptor expression in Bergmann glia was more variable than that in Purkinje cells. We found that physical damage with inflammation induced the selective upregulation of the oxytocin receptor in Bergmann glia. Our findings indicate high variability in oxytocin receptor expression in the cerebellum and suggest that the oxytocin receptor can affect neural processing in pathological conditions, such as inflammation.
GSK2239633 is a human chemokine receptor 4 (CCR4) antagonist with a novel anti-inflammatory profile acting mainly on a subset of Th2 cells, with potential for the oral treatment of all severities of asthma. Inhibition of the CCR4 receptor represents a target for asthma because of the potential to inhibit Th2 cell chemotaxis and the subsequent effects of limiting Th2 cell involvement in both the acute and chronic inflammatory response. Recent data in man suggests that the CCR4 receptor ligands (thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC)) may be important in asthma and in the development of Allergic Bronchopulmonary Aspergillosis (ABPA). This will provide a unique opportunity to differentiate GSK2239633 significantly from other oral non-steroidal asthma treatments. This study is the first administration of oral GSK2239633 in humans. Two alternating cohorts of 12 subjects will receive 3 single, ascending doses of oral GSK2239633 or placebo. In addition, one cohort will receive a single dose of GSK2239633 or placebo following the standard FDA high fat/high calorie meal. Safety will be monitored (ECGs, telemetry, vital signs, clinical laboratory assessments, adverse events), and blood samples will be taken for pharmacokinetic and pharmacodynamic analysis.
Participants on background PAH therapy will receive sotatercept subcutaneous (SC) injections at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks up to 24 weeks. Thereafter, participants may choose to continue receiving the treatment until approval of sotatercept in Japan.
Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
BACKGROUND: Triglyceride-glucose (TyG) index is linked to a poor prognosis for cardiovascular condition and is a valid indicator of insulin resistance. This study evaluated the potential predicting usefulness of the TyG index for all-cause mortality, both short- and long-term, for those concerning critical coronary artery disease (CAD).
METHODS: In this study, information from 5452 critically-ill individuals with CAD in intensive care units were gathered from the Medical Information Marketplace in Intensive Care (MIMIC-IV) database. Depending on the TyG index degree, the patients were categorized into three categories. Clinical outcomes included short-term (30-day) and long-term (365-day) all-cause mortality. The corresponding relationships involving the TyG index and clinical outcomes were examined by deploying restricted cubic spline (RCS) regression analysis and Cox proportional risk regression.
RESULTS: An increased TyG index was associated with increased 30-day (Tertile 1: 6.1%, Tertile 2: 7.3%, Tertile 3: 9.2%, P = 0.001) and 365-day (Tertile 1: 15.2%, Tertile 2: 17.0%, Tertile 3: 19.6%, P = 0.002) death rates across all causes. Cox regression with multiple variables indicates that higher TyG indices were linked to higher all-caused mortality hazard ratios throughout the short and long terms, with a larger predictive value for the former. RCS regression analyses suggested that the risk of death was notably and linearly that is associated with TyG index.
CONCLUSIONS: The TyG index is a reliable predictor of all-cause mortality at different stages in critically ill CAD patients, with a higher predictive ability for short-term mortality. Early intervention in patients with elevated TyG index may improve their survival outcomes. Future research should delve into understanding its pathophysiological mechanisms and develop intervention strategies based on the TyG index, providing new insights and strategies to enhance the outlook for critically ill CAD patients.
PURPOSE: Paraovarian cysts in children and adolescents can be challenging to accurately diagnose prior to surgery. Our objective is to outline the clinical characteristics of paraovarian cysts and enhance the precision of diagnosing paraovarian cysts in this age group.
METHODS: We retrospectively analyzed all patients with paraovarian cysts who underwent surgery in our department from 2013 to 2021. The review focused on demographic characteristics, clinical manifestations, intraoperative findings, and postoperative pathology of these patients.
RESULTS: This cohort was composed of 38 children with paraovarian cysts. The average diameter of the cysts was 4.8 cm (range 0.5-10 cm). Among the cases, 25 (65.8%) had adnexal torsion. Postoperative pathology showed that all cases were simple cysts with serous fluid. After the procedure, the patients were monitored for a period ranging from 12 to 108 months. B-ultrasound and physical examination did not reveal any significant abnormalities.
CONCLUSIONS: B-ultrasound can help diagnose paraovarian cysts by detecting slight deviation movement between the cyst and the uterus. The presence of adnexa torsion in children and adolescents with paraovarian cysts does not depend on BMI, but rather on the size of cysts. Laparoscopic cyst removal has proven to be an effective surgical approach with favorable outcomes.
Myocardial infarction is a worldwide disease with high morbidity and mortality and a major cause of chronic heart failure, seriously affecting patients' quality of life. Natural medicine has been used to cure or prevent cardiovascular disease for decades. As a natural flavonoid, anthocyanidin has been used to treat many diseases due to its antioxidative, anti-inflammatory, and other properties. A mouse model (C57BL/6) weighing 30-40 g was utilized to induce myocardial infarction by ligating the left anterior descending coronary artery. Cyanidin (30 mg/kg) was administered orally to mice for four weeks. A variety of assessments were used to evaluate cardiac function. The gene expression was measured using RNAseq and Western blot. Histological changes in myocardial tissue were assessed using staining techniques, including Masson, Hematoxylin Eosin (HE), and transmission electron microscopy. Tunnel staining was implemented as a method to detect cellular apoptosis. For the quantification of B-type natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) in the serum, an enzyme-linked immunosorbent assay (ELISA) was employed. Furthermore, autodock simulation was executed in order to assess the interaction between cyanidin and a subset of genes. Cyanidin treatment inhibited myocardial cell apoptosis, improved cardiac function, and reduced serum concentrations of BNP and atrial natriuretic peptide ANP, as well as mitigated histological cardiac tissue damage. Cyanidin also inhibited the activity of matrix metalloproteinases (MMP2/9) and Fibronectin 1 (Fn1). Cyanidin improves heart function and reduces myocardial damage in mice after MI. Furthermore, cyanidin can prevent cardiomyocyte apoptosis. These effects are most likely caused by suppression of MMP9/2 and control of the Akt signaling pathway, suggesting an appropriate therapeutic target.
Safety and efficacy of CHANTIX in combination with other smoking cessation therapies have not been studied.

Varenicline (1 mg twice daily) did not alter the steady-state pharmacokinetics of bupropion (150 mg twice daily) in 46 smokers. The safety of the combination of bupropion and varenicline has not been established. Bupropion:

: Although co-administration of varenicline (1 mg twice daily) and transdermal nicotine (21 mg/day) for up to 12 days did not affect nicotine pharmacokinetics, the incidence of nausea, headache, vomiting, dizziness, dyspepsia, and fatigue was greater for the combination than for NRT alone. In this study, eight of twenty-two (36%) patients treated with the combination of varenicline and NRT prematurely discontinued treatment due to adverse events, compared to 1 of 17 (6%) of patients treated with NRT and placebo. Nicotine replacement therapy (NRT)
This group will be prescribed a daily GL of \>75 points/1000kcal and 60% of daily calorie intake from carbohydrates. This group will be provided more processed foods than the low GL group. During the first 16 weeks, this group will eat enough calories to maintain baseline weight, and will reduce daily calorie intake by 500 kcal/day in the second 16 weeks.
A data management system accepts input documents having a variety of formats from multiple sources. Typically one or more formats are associated with a source. A document reader parses an input documents using a set of rules. The rules are tailored to the source that provided the document. The rules use format and context to extract data. The data extracted from the input document is stored in a document database and indexed. Typically, demographic data and clinical data are extracted from the input document and the demographic data is used to index the document.
Many different intervention program have been used throughout the world. One alternative method used to teach children is the social stories method, which was created by Gray (1993) to address the social difficulties of children with ASD. The theoretical framework of the social stories is based on theory of mind (TOM) hypothesis. Difficulties associated with the impaired TOM was addressed by explaining the complex social concepts in simple words and often include the description of perspectives of others. Several studies have shown the efficacy of the social story intervention. It is usually provided individually, but we want to use it in the group.

In this study, we plan to randomly assign thirty-six 5-7-year-old children with ASD to one of two kinds of social skills groups: the social skills group or the play activities group (control condition). Group met for 16 weeks, one time per week, one hour each time. Participants were recruited between October 2020 and September 2023. Assessment were conducted at baseline and endpoint (16 weeks). To empower parents, we would also ask parents of participants to attend our treatment and lecture.
Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (\~30).